Close
Help




JOURNAL

Clinical Medicine Reviews in Oncology

Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin

Submit a Paper


Clinical Medicine Reviews in Oncology 2011:3 93-105

Review

Published on 24 Aug 2011

DOI: 10.4137/CMRO.S1605


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Oncology

Abstract

Ovarian cancer (OVCA) and soft tissue sarcoma (STS) are cancers that cause low survival rates when diagnosed at advanced disease stage and patients with these cancers usually suffer from recurrent disease. Trabectedin, an alkaloid of marine origin has recently demonstrated improvement in managing advanced recurrent OVCA and STS. It is currently approved as a single therapeutic agent for second line therapy of STS in the USA and Europe. It is also approved in combination with pegylated liposomal doxorubicin as a second line therapy for OVCA in Europe. This review summarizes recent clinical data demonstrating the efficacy of using trabectedin as a second line therapy in OVCA and in STS.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Reviews in Oncology
The process of submitting the paper was smooth with little time required on the author's behalf. Reviews were prompt and the process of addressing reviewer comments was very streamlined. All correspondence with the editorial office was extremely professional with immediate responses. This is one of the few journals asking for feedback on their submission process.
Dr Greg Trottier, MD, PhD, FRCSC (University of Toronto, Toronto, Ontario, Canada)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube